According to the
New York Times, the AKF has favored patients from clinics that contributed to the Kidney Fund, and discouraged other clinics from applying for assistance.
Fresenius and
DaVita provide nearly 80% of the AKF's funding. According to Tracey Dickey, a social worker, the Kidney Fund sent her guidelines which said that "If your company cannot make fair and equitable contributions, we respectfully request that your organization not refer patients." LaVarne A. Burton, the Kidney Fund's chief executive, said that Dickey had misunderstood the guidelines. In a statement on its website, the AKF called the article "factually incorrect and unfair", and said that they have never turned away a patient who was financially qualified to receive a grant, and that 40% of dialysis providers with patients receiving help do not contribute anything to the AKF. The U.S.
Centers for Medicare and Medicaid Services (CMS) charged that dialysis providers steered patients to private insurance companies, which cost patients more, rather than to Medicaid and Medicare, which cost patients less but had lower reimbursements for the providers. The providers used the AKF's subsidies to help patients buy the more-expensive private insurance, according to the CMS. According to the
Wall Street Journal, "The rule took aim at a setup that has come under fire from health insurers, particularly those offering plans on the
Affordable Care Act’s marketplaces. Under the setup, dialysis patients get help paying their health-insurance premiums from a charity, which itself gets funding from dialysis providers." ==See also==